Literature DB >> 20828814

Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.

Sarah A Holstein1, Raymond J Hohl.   

Abstract

Myeloma is characterized by the overproduction and secretion of monoclonal protein. Inhibitors of the isoprenoid biosynthetic pathway (IBP) have pleiotropic effects in myeloma cells. To investigate whether IBP inhibition interferes with monoclonal protein secretion, human myeloma cells were treated with specific inhibitors of the IBP or prenyltransferases. These studies demonstrate that agents that inhibit Rab geranylgeranylation disrupt light chain trafficking, lead to accumulation of light chain in the endoplasmic reticulum, activate the unfolded protein response pathway and induce apoptosis. These studies provide a novel mechanism of action for IBP inhibitors and suggest that further exploration of Rab-targeted agents in myeloma is warranted.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20828814      PMCID: PMC3038195          DOI: 10.1016/j.leukres.2010.08.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  38 in total

1.  More than 1,000 putative new human signalling proteins revealed by EST data mining.

Authors:  J Schultz; T Doerks; C P Ponting; R R Copley; P Bork
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response.

Authors:  Yanjun Ma; Joseph W Brewer; J Alan Diehl; Linda M Hendershot
Journal:  J Mol Biol       Date:  2002-05-17       Impact factor: 5.469

3.  Lovastatin is a potent inhibitor of cholecystokinin secretion in endocrine tumor cells in culture.

Authors:  D Vishnuvardhan; M C Beinfeld
Journal:  Peptides       Date:  2000-04       Impact factor: 3.750

4.  Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.

Authors:  J D Bergstrom; R G Bostedor; P J Masarachia; A A Reszka; G Rodan
Journal:  Arch Biochem Biophys       Date:  2000-01-01       Impact factor: 4.013

5.  Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB.

Authors:  Sarah A Holstein; Christine L Wohlford-Lenane; Raymond J Hohl
Journal:  J Biol Chem       Date:  2002-01-11       Impact factor: 5.157

6.  Isoprenoids influence expression of Ras and Ras-related proteins.

Authors:  Sarah A Holstein; Christine L Wohlford-Lenane; Raymond J Hohl
Journal:  Biochemistry       Date:  2002-11-19       Impact factor: 3.162

7.  Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.

Authors:  F P Coxon; M H Helfrich; B Larijani; M Muzylak; J E Dunford; D Marshall; A D McKinnon; S A Nesbitt; M A Horton; M C Seabra; F H Ebetino; M J Rogers
Journal:  J Biol Chem       Date:  2001-10-01       Impact factor: 5.157

8.  The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models.

Authors:  Satoko Ohno; Mitsuru Yoshimoto; Saho Honda; Sae Miyachi; Tadao Ishida; Fumio Itoh; Takao Endo; Susumu Chiba; Kohzoh Imai
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

9.  The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells.

Authors:  N W C J van de Donk; M M J Kamphuis; H M Lokhorst; A C Bloem
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

10.  Rapid degradation of dominant-negative Rab27 proteins in vivo precludes their use in transgenic mouse models.

Authors:  José S Ramalho; Ross Anders; Gesine B Jaissle; Mathias W Seeliger; Clare Huxley; Miguel C Seabra
Journal:  BMC Cell Biol       Date:  2002-10-28       Impact factor: 4.241

View more
  25 in total

1.  N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.

Authors:  Xiang Zhou; Ella J Born; Cheryl Allen; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2015-04-17       Impact factor: 2.823

2.  In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

3.  ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.

Authors:  Nazmul H Bhuiyan; Michelle L Varney; Deep S Bhattacharya; William M Payne; Aaron M Mohs; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2019-08-20       Impact factor: 2.823

4.  Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Daryl J Murry; Sarah A Holstein
Journal:  Invest New Drugs       Date:  2018-03-02       Impact factor: 3.850

5.  Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase.

Authors:  Veronica S Wills; Cheryl Allen; Sarah A Holstein; David F Wiemer
Journal:  ACS Med Chem Lett       Date:  2015-10-28       Impact factor: 4.345

6.  Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Authors:  Jacqueline E Reilly; Jeffrey D Neighbors; Huaxiang Tong; Michael D Henry; Raymond J Hohl
Journal:  Clin Exp Metastasis       Date:  2015-06-13       Impact factor: 5.150

7.  Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors.

Authors:  Daniel B Goetz; Michelle L Varney; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2020-06-30       Impact factor: 3.641

8.  A new motif for inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Benjamin J Foust; Cheryl Allen; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem       Date:  2016-06-10       Impact factor: 3.641

9.  Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Xiang Zhou; Sarah D Ferree; Veronica S Wills; Ella J Born; Huaxiang Tong; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2014-03-24       Impact factor: 3.641

10.  Triazole-based inhibitors of geranylgeranyltransferase II.

Authors:  Xiang Zhou; Sara V Hartman; Ella J Born; Jacqueline P Smits; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.